Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)-Reference-Cited by-同舟云学术

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)

Published:2013-06-13 Issue:9 Volume:33 Page:1398-1405
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Verma Siddharth¹,Jensen Donald²,Hart John³,Mohanty Smruti R.¹

Affiliation:

1. Division of Gastroenterology & Hepatology; Center for Liver Diseases; New York Methodist Hospital at Weill Cornell Medical College; Brooklyn NY USA

2. Department of Medicine; Center for Liver Disease; University of Chicago Medical Center; Chicago IL USA

3. Department of Pathology; University of Chicago Medical Center; Chicago IL USA

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12226/fullpdf

Reference42 articles.

1. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity;Matteoni;Gastroenterology,1999

2. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome;Marchesini;Hepatology,2003

3. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease;Angelico;J Clin Endocrinol Metab,2005

4. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases;Angelico;J Gastroenterol Hepatol,2003

5. Silent non-alcoholic fatty liver disease-a clinical-histological study;Sorrentino;J Hepatol,2004

Cited by 255 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries;Archives of Medical Research;2024-09

2. Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial;The American Journal of Clinical Nutrition;2024-09

3. Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis;Metabolism and Target Organ Damage;2024-08-22

4. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Impact on Fibrosis Risk in Inactive Chronic Hepatitis B Patients: Insights from a Cross-Sectional Study;Journal of Clinical Medicine;2024-08-12

5. Establish a noninvasive model to screen metabolic dysfunction-associated steatotic liver disease in children aged 6–14 years in China and its applications in high-obesity-risk countries and regions;The Lancet Regional Health - Western Pacific;2024-08